Clinical Trial Update: Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for DPX-Survivac in recurrent ovarian-related cancers, spanning Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Peritoneal Cancer

Drugs mentioned

• DPX-Survivac

Snippet

Sponsor: ImmunoVaccine Technologies, Inc. (IMV Inc.) | Conditions: Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer | Phase 1, Phase 2 | Status: UNKNOWN